SGEN Seattle Genetics, Inc.

63.22
+0  (0%)
Previous Close 63.03
Open 62.99
Price To book 14.14
Market Cap 9.01B
Shares 142,493,000
Volume 658,429
Short Ratio 11.52
Av. Daily Volume 1,044,720

SEC filingsSee all SEC filings

  1. 8-K - Current report 17680178
  2. 8-K - Current report 17666451
  3. CT ORDER - Confidential treatment order 17639795
  4. CT ORDER - Confidential treatment order 17631131
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17625891

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017.
Vadastuximab Talirine (SGN-CD33A)
Frontline Acute Myeloid Leukemia (AML)
Phase 3 initiated May 2016. Enrollment ongoing as of February 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
Phase 3 data due in 2017.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 data released August 2016. sNDA to be filed mid 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23, 2017
  2. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  3. Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
  4. Coverage initiated on Seattle Genetics by Oppenheimer
  5. Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?
  6. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  7. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN
  8. Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)
  9. INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  10. March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
  11. DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN
  12. SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events
  13. Why Immunomedics, Inc. Jumped Higher Today
  14. Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
  15. Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold
  16. Immunomedics Soars on Injunction Against Seattle Genetics Deal
  17. Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics, Inc.
  18. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017
  19. Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
  20. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN